Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

doi:10.1186/1471-2407-13-49

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

BMC cancer - 2 Feb 2013

Pentheroudakis George, Kotoula Vassiliki, De Roock Wendy, Kouvatseas George, Papakostas Pavlos, Makatsoris Thomas, Papamichael Demetris, Xanthakis Ioannis, Sgouros Joseph, Televantou Despina, Kafiri Georgia, Tsamandas Athanassios C, Razis Evangelia, Galani Eleni, Bafaloukos Dimitrios, Efstratiou Ioannis, Bompolaki Iliada, Pectasides Dimitrios, Pavlidis Nicholas, Tejpar Sabine, Fountzilas George

Abstract excerpt

BACKGROUND: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order to identify additional biomarkers of cetuximab efficacy. METHODS: Previously genotyped (KRAS, NRAS, BRAF, PIK3CA mutations) formalin-fixed paraffin-embedded tumour biopsies of 226...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Epidermal Growth Factor

Share to Genes, ras

Share to Glycoproteins

Share to Intercellular Signaling Peptides and Proteins

Share to Phosphatidylinositol 3-Kinase

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 23374602
DOI: 10.1186/1471-2407-13-49
PMCID: PMC3599697

Genes

KRAS
AREG
EGFR
EREG
BRAF
NRAS
EGF
TGFA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.PMID 23374602Read ↗

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.Semantic proximity Read ↗

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.Semantic proximity Read ↗

Anti-EGFR therapy in colorectal cancer: how to choose the right patient.Semantic proximity Read ↗

Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.Semantic proximity Read ↗

Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.Semantic proximity Read ↗

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read ↗

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.